Which hormones, metabolic markers, and bone density indicators to test — and when. Includes optimal ranges for peri- and post-menopausal women and how to interpret trending values over time.
The menopausal transition makes single-point lab testing unreliable. Estradiol can swing from 20 to 300 pg/mL within weeks. FSH may be 40 one month and 20 the next. Progesterone depends entirely on whether ovulation occurred that cycle. This volatility doesn't mean testing is useless — it means you need to track trends over time rather than react to any single result.
The goal is to build a biomarker trajectory that shows you: where you are in the transition, how your metabolic health is shifting, whether interventions (exercise, nutrition, HRT) are working, and where emerging risks are developing before they become clinical problems.
These markers confirm menopausal staging and guide HRT decisions.
| Marker | Standard Range | Longevity-Optimal | Notes |
|---|---|---|---|
| FSH | Varies by phase | Context-dependent | Rising FSH (>25 mIU/mL) confirms perimenopause. Draw on cycle day 2–5 if still cycling. Levels >40 with 12 months amenorrhea confirm menopause. |
| Estradiol (E2) | Varies by phase | On HRT: 50–100 pg/mL | Highly variable during perimenopause. Post-menopause without HRT: typically <30 pg/mL. On HRT, aim for physiological replacement levels. |
| Progesterone | >5 ng/mL (luteal) | >10 ng/mL (luteal) | Draw on cycle day 21 if cycling. Low progesterone (<5) during luteal phase suggests anovulation — a hallmark of perimenopause. |
| AMH | Age-dependent | Declining is expected | Most stable marker of ovarian reserve. <1.0 ng/mL at any age suggests accelerated ovarian aging. Undetectable in postmenopause. |
| Total Testosterone | 15–70 ng/dL | 25–50 ng/dL | Declines ~1–2%/year from mid-30s. Low levels contribute to fatigue, reduced libido, and muscle loss. Always interpret with SHBG. |
| Free Testosterone | 0.3–1.9 pg/mL | 0.8–1.5 pg/mL | Better indicator of bioavailable testosterone than total. Calculated or measured directly. |
| SHBG | 18–144 nmol/L | 40–80 nmol/L | Rises with oral estrogen (reducing free testosterone). Oral HRT increases SHBG more than transdermal — this matters for libido. |
| DHEA-S | Age-dependent | 100–300 μg/dL | Adrenal androgen precursor. Declines with age; very low levels may contribute to fatigue and immune dysfunction. |
During perimenopause, draw FSH and estradiol on cycle day 2–5 (early follicular phase) for the most interpretable results. If cycles are too irregular to time, draw on any day but note where you are in the cycle. For progesterone, draw on day 21 (or 7 days after expected ovulation). Post-menopause: timing doesn't matter — draw anytime.
The menopausal transition accelerates metabolic changes that drive cardiovascular and diabetes risk. These markers are often more important for long-term health outcomes than the reproductive hormones themselves.
| Marker | Standard Range | Longevity-Optimal | Why It Matters |
|---|---|---|---|
| Fasting Insulin | <25 μIU/mL | <5 μIU/mL | The earliest marker of insulin resistance. Rises during menopause even in previously insulin-sensitive women. Track every 6 months. |
| HbA1c | <5.7% | <5.2% | 3-month average blood sugar. Standard "normal" range allows significant metabolic dysfunction. Aim for <5.2%. |
| Fasting Glucose | 65–99 mg/dL | 72–85 mg/dL | Should remain stable. Rising fasting glucose (even within "normal") may indicate developing insulin resistance. |
| HOMA-IR | <2.5 | <1.0 | Calculated from fasting glucose and insulin. The most sensitive composite marker of insulin resistance. Rising HOMA-IR during menopause warrants dietary and exercise intervention. |
| ApoB | <130 mg/dL | <80 mg/dL | The single best predictor of cardiovascular risk from lipids. Rises with declining estrogen. More important than LDL cholesterol. |
| LDL Cholesterol | <130 mg/dL | <100 mg/dL | Increases 10–15% during menopausal transition. ApoB is preferred if available, but LDL tracking still valuable. |
| HDL Cholesterol | >50 mg/dL | >65 mg/dL | Cardioprotective. Women typically have higher HDL than men, but this advantage narrows after menopause. |
| Triglycerides | <150 mg/dL | <80 mg/dL | Strongly correlated with insulin resistance. Elevated TG/HDL ratio (>2) is a red flag for metabolic dysfunction. |
| Lp(a) | <30 mg/dL | <30 mg/dL | Genetically determined; rises with declining estrogen. Test once — if elevated, it's an independent cardiovascular risk factor that changes your risk calculus for HRT. |
| hs-CRP | <3.0 mg/L | <0.5 mg/L | Systemic inflammation marker. Tends to rise during menopause with increasing visceral fat. Strongly linked to cardiovascular events. |
Women commonly see LDL rise 10–15%, ApoB increase, triglycerides drift upward, and HDL decline during the menopausal transition — even with no dietary changes. This isn't "getting older" — it's estrogen loss directly affecting hepatic lipid metabolism. Track these markers every 6 months during the transition to catch accelerating risk early. Our Lab Results Interpreter can help you understand your numbers.
| Marker | Optimal Range | Frequency | Notes |
|---|---|---|---|
| DEXA Scan (T-score) | T-score > -1.0 | Baseline at 45–50; repeat every 2 years | Osteopenia: -1.0 to -2.5. Osteoporosis: < -2.5. Fastest bone loss occurs 1 year before to 2 years after final period. |
| Vitamin D (25-OH) | 40–60 ng/mL | Every 6–12 months | Critical for calcium absorption and bone health. Most women are suboptimal without supplementation. Dose to target. |
| Calcium (serum) | 8.6–10.2 mg/dL | Annually | Serum calcium is tightly regulated and rarely abnormal. More useful to track dietary calcium intake (target: 1,200 mg/day). |
| TSH | 0.5–2.5 mIU/L | Annually | Thyroid dysfunction increases with age and can mimic menopause symptoms. Standard "normal" range (0.4–4.5) is too wide. |
| Free T4 | 1.0–1.5 ng/dL | If TSH abnormal | Confirms thyroid function when TSH is borderline. Add Free T3 for complete picture. |
| Free T3 | 3.0–4.0 pg/mL | If symptomatic | Active thyroid hormone. Low Free T3 with normal TSH ("low T3 syndrome") can cause fatigue, cold intolerance, weight gain. |
| Ferritin | 50–150 ng/mL | Annually | Iron storage. May rise after periods stop (no monthly iron loss). Elevated ferritin (>200) is worth investigating. |
| Magnesium (RBC) | 5.0–6.5 mg/dL | Annually | RBC magnesium is more accurate than serum magnesium. Deficiency is common and affects bone health, sleep, and muscle function. |
| B12 | >500 pg/mL | Annually | Absorption decreases with age. Deficiency causes fatigue, cognitive issues, and neuropathy. Methylmalonic acid (MMA) is a more sensitive marker. |
Establish baselines. Get a comprehensive panel now — before things change dramatically. This gives you comparison points for the years ahead.
Increase frequency to every 6 months for hormones and metabolic markers. This is the period of most rapid change.
Annual testing is typically sufficient once hormones and metabolic markers stabilize.
Use our Blood Panel Builder to create a custom testing plan with Quest/LabCorp codes. Then use the Lab Results Interpreter to understand your results against longevity-optimal ranges — not just standard "normal" ranges.
This is expected and not alarming. It confirms you're moving through the transition. Track the rate of change — rapid AMH decline suggests accelerated ovarian aging.
This is actionable. Even small increases in fasting insulin (from 3 to 6, or 6 to 10) signal emerging insulin resistance. Increase resistance training, reduce refined carbohydrates, and consider time-restricted eating. Retest in 3 months.
Expected during the transition but still requires attention. If ApoB rises above 90 mg/dL, discuss statin or other lipid-lowering therapy with your provider — especially if you have additional risk factors.
A decline of more than 3–5% between scans warrants intervention. Ensure adequate calcium (1,200 mg/day), vitamin D (40–60 ng/mL), and resistance + impact exercise. If T-score drops below -2.0, discuss bisphosphonates or HRT with your provider. See our Bone Density Optimization Protocol.
Common during menopause as visceral fat increases. Address through exercise, sleep optimization, omega-3 supplementation, and dietary anti-inflammatory patterns (Mediterranean diet). Persistent hs-CRP above 2.0 mg/L warrants further cardiovascular evaluation.
Use our Blood Panel Builder to select the right tests with Quest and LabCorp codes.
Build Your Panel →